Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Srikakulam: In a serious breach of supply chain and internal controls, a group of eight individuals, including current and ...

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from ...

Estonian residents spent more on weight-loss drugs like Ozempic than any other medication last year, with one in every 50 ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Influencers on TikTok have been banned after they were found to be promoting drugs like Ozempic and Mounjaro through their social media ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2025” report provides comprehensive insights about 80+ ...